Are patients with non-ST elevation myocardial infarction undertreated?
Saman Rasoul1, Jan Paul Ottervanger, Jan-Henk E Dambrink
1Isala Klinieken, Dept of Cardiology, Zwolle, The Netherlands. s.rasoul@isala.nl <s.rasoul@isala.nl>
BMC Cardiovascular Disorders
|March 7, 2007
Summary
Patients with non-ST-elevation myocardial infarction (non-STEMI) had worse outcomes than STEMI patients, but this was linked to older age and less aggressive treatment, not the non-STEMI diagnosis itself. Optimized treatment may improve non-STEMI patient survival.
Area of Science:
- Cardiology
- Internal Medicine
- Clinical Research
Background:
- Patients with non-ST-elevation myocardial infarction (non-STEMI) often have poorer prognoses compared to ST-elevation myocardial infarction (STEMI).
- Treatment disparities may contribute to the observed outcome differences between non-STEMI and STEMI patients.
- This study evaluates characteristics, treatment, and outcomes in an unselected population to understand these differences.
Purpose of the Study:
- To compare patient characteristics, treatment strategies, and long-term outcomes between non-STEMI and STEMI patients.
- To identify factors influencing mortality in myocardial infarction (MI) patients.
- To assess whether the non-STEMI diagnosis itself predicts mortality independently of other clinical factors.
Main Methods:
- Individual patient data from 824 MI patients discharged between January 2001 and January 2002 were analyzed.
- Patients were classified as non-STEMI or STEMI based on presenting electrocardiogram.
- Follow-up data were collected until December 2004 to determine long-term mortality.
Main Results:
- Non-STEMI patients were older with a higher cardiovascular risk profile.
- Non-STEMI patients received less frequent coronary angiography, revascularization, and fewer discharge medications like clopidogrel and ACE-inhibitors.
- Long-term mortality was higher in non-STEMI (20%) versus STEMI (12%) patients, but multivariate analysis identified age, diabetes, hypertension, and lack of reperfusion therapy as independent predictors, not the non-STEMI presentation.
Conclusions:
- Significant differences exist in baseline characteristics and invasive treatment between STEMI and non-STEMI patients.
- Observed mortality differences are attributable to variations in patient profiles and treatment, rather than the non-STEMI diagnosis alone.
- Implementing more aggressive treatment strategies for non-STEMI patients could potentially enhance their long-term outcomes.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:27Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...